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OBJECTIVE: The angiotensin-converting enzyme gene is one of the most studied candidate genes related to
atrial fibrillation. Among the polymorphisms of the angiotensin-converting enzyme gene, the 2350 G/A
polymorphism (rs4343) is known to have the most significant effects on the plasma angiotensin-converting
enzyme concentration. The aim of the present study was to investigate the association of the angiotensin-
converting enzyme 2350 G/A polymorphism with atrial fibrillation in Han Chinese patients with essential
hypertension.
METHODS: A total of 169 hypertensive patients were eligible for this study. Patients with atrial fibrillation
(n=75) were allocated to the atrial fibrillation group, and 94 subjects without atrial fibrillation were allocated
to the control group. The PCR-based restriction fragment length polymorphism technique was used to assess
the genotype frequencies.
RESULTS: The distributions of the angiotensin-converting enzyme 2350 G/A genotypes (GG, GA, and AA,
respectively) were 40.43%, 41.49%, and 18.08% in the controls and 18.67%, 46.67%, and 34.66% in the atrial
fibrillation subjects (p=0.037). The frequency of the A allele in the atrial fibrillation group was significantly
greater than in the control group (58.00% vs. 38.83%, p=0.0007). Compared with the wild-type GG genotype,
the GA and AA genotypes had an increased risk for atrial fibrillation. Additionally, atrial fibrillation patients
with the AA genotype had greater left atrial dimensions than the patients with the GG or GA genotypes
(p,0.01 and p,0.05, respectively).
CONCLUSIONS: The results obtained in this study indicate that the angiotensin-converting enzyme 2350 G/A
polymorphism is associated with atrial fibrillation and that the A allele shows an increased risk for atrial
fibrillation in Han Chinese patients with essential hypertension.
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& INTRODUCTION
Atrial fibrillation (AF) is a rapidly evolving epidemic,
representing a multifactorial, dynamic disorder with serious
health consequences (1-6). The prevalence of AF is strongly
age-dependent, affecting approximately 0.5% of persons
aged 40-50 years old and 5-15% of individuals aged 80 years
old (3,7). In China, the morbidity related to AF is 0.77% in
the adult population (8). AF not only is an independent risk
factor for death but also confers a significant risk of
morbidity from stroke associated with cardiogenic throm-
boembolisms (9,10). Despite current achievements in the
pharmacological and non-pharmacological treatments of
AF, its management remains a difficult task (2).
Essential hypertension (EH) is the most common cardiac
condition associated with AF (11). The risk of AF in EH
subjects, compared with normotensive subjects, was
increased by 1.9 times in the Framingham Heart Study
(12) and by 1.4 times in the Manitoba Follow-up Study (13).
However, contemporary approaches to prevent AF in EH
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patients have been limited by inefficacy and intolerance
(14).
Recently, the rennin-angiotensin system (RAS) has been
implicated in the development of AF (15-17), and the
inhibition of RAS activity has been shown to reduce AF
vulnerability (18). Therefore, over the past decade, the key
enzyme of this system, the angiotensin-converting enzyme
(ACE), has become one of the most studied candidate genes
in AF. Many studies have attempted to shed some light on
the possible association between the ACE gene insertion/
deletion (I/D) polymorphism and the risk of AF. However,
previous reports have shown inconsistent and even contra-
dictory results (2).
The physiological role of the I/D polymorphism has not
yet been clarified. This polymorphism is likely in strong
linkage disequilibrium with another functional mutation
within the gene (19). Recently, a genome-scan analysis by
the Framingham Heart Study found strong evidence for a
quantitative-trait locus on chromosome 17 that was close to
the ACE gene (20). Among the 13 polymorphisms of the
ACE gene recently reported, a dimorphism in exon 17,
2350G/A (rs4343), had the most significant effects on the
plasma ACE concentration (21).
Based on these findings, we conducted a case-control
study of the ACE 2350 G/A polymorphism for a putative
association with AF in Han Chinese patients with EH.
& MATERIALS AND METHODS
A total of 169 patients with EH were eligible for this study.
They were all unrelated Han nationality residents and were
enrolled at the Affiliated Hospital of Nantong University.
Patients with AF (n= 75) were allocated to the AF group, and
94 subjects without AF were allocated to the control group.
EH was defined according to the Joint National Committee
on the Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC-7) criteria (22). AF was defined
according to the European Society of Cardiology (ESC)
Guidelines for the management of AF (3), based on the
replacement of sinus P waves by rapid oscillations or
fibrillatory waves that varied in size, shape, and timing,
which were associated with an irregular ventricular response
when atrioventricular conduction was intact. The presence of
AF was determined based on patient history, followed by
serial electrocardiography or ambulatory electrocardio-
graphic monitoring. Details regarding the medical history,
family history, and clinical symptoms were obtained from all
participants using a standardized questionnaire in addition
to information on drug intake and cigarette smoking. Blood
pressure, height, weight, and waistline were measured by
trained physicians or nurses, according to standardized
protocols. Patients were excluded if they had acute coronary
syndrome; hypertrophic cardiomyopathy; significant valvu-
lar disease; left ventricular dysfunction (ejection fraction
,50%); or neoplastic, renal, liver, or thyroid diseases. All
study participants were unrelated Han nationality residents.
The study was approved by the Medical Ethics Committee of
Nantong University, and written informed consent was
obtained from all participants.
Venous blood samples were obtained after at least a 10-
hour overnight fast. The samples were then centrifuged at
2500 rpm for 30 minutes at 4 C˚ and immediately stored at -
80 C˚ until analysis. Themeasurement of total cholesterol (TC),
high-density lipoprotein-cholesterol (HDL-C), low-density
lipoprotein-cholesterol (LDL-C), and triglycerides (TG) was
performed as described previously (7,19).
Genomic DNA was extracted from peripheral blood
leukocytes by the salting-out method, with minimal
modifications. The determination of the ACE 2350 G/A
genotypes was performed by polymerase chain reaction and
restriction fragment length polymorphism (PCR-RFLP)
analysis, as described previously (19,23,24).
All continuous variables are expressed as means and
standard deviations (SDs). Student’s t-test and analysis of
variance (ANOVA), followed by the Newman-Keuls test,
were used to compare continuous variables between two
groups and among multiple groups, respectively. The
genotype and allele frequencies were obtained by direct
counts. Differences in the distributions of the alleles and
genotypes between the groups and the deviation from
Hardy-Weinberg equilibrium were assessed by the x2 test.
All significant tests were two-tailed and were considered
statistically significant at p,0.05. SAS software (version 8,
SAS Institute, Cary, NC, USA) was used in all statistical
analyses. The present sample size of 169 — 75 AF patients
and 94 controls — revealed an 87.28% power to detect a
significant association (a,0.05) for a 7% prevalence of AF in
the population (8) using the dominant inheritance model.
& RESULTS
The clinical characteristics of all the participants enrolled
in the study are depicted in Table 1. No significant
differences were observed between the two groups with
regard to age, gender, body mass index (BMI), blood
pressure, left ventricular ejection fraction (LVEF), serum
lipid levels, diabetes, smoking status, or the use of
antihypertensive drugs. However, compared with the
controls, the AF patients had larger left atrial dimensions.
Table 2 summarizes the distribution of the ACE 2350 G/A
genotypes and allele frequencies for the two groups. The
genotype distribution among the subjects was in Hardy-
Weinberg equilibrium in both the control (x2= 1.5071,
p=0.2196) and AF (x2= 0.1332, p= 0.7151) groups. The
distributions of the ACE 2350 G/A genotypes (GG, GA,
andAA, respectively) were 40.43%, 41.49%, and 18.08% in the
controls and 18.67%, 46.67%, and 34.66% in the AF subjects
(p= 0.037). The frequency of the A allele in the AF group was
significantly greater than in the control group (58.00% vs.
38.83%, p=0.0007). Compared with the wild-type GG
genotype, the GA genotype had a 2.44-fold increased risk
of AF (95% confidence interval [CI] = 1.1346-5.2297,
p=0.0261), and the AA genotype had a 4.15-fold increased
risk of AF (95% CI= 1.7469-9.8650, p=0.0016). After adjust-
ments for gender, age, BMI, blood pressure, LVEF, plasma
lipid parameters, smoking status, prevalence of diabetes, and
left atrial dimensions, these associations persisted.
The effects of the different genotypes on the clinical
parameters are shown in Table 3. There were no significant
differences regarding gender, age, BMI, blood pressure, or
serum lipid parameters between the genotypes in the AF
and control groups. However, the AF patients with the AA
genotype had greater left atrial dimensions than the patients
with the GG and GA genotypes (p,0.01, p,0.05).
& DISCUSSION
ACE is a dipeptidyl carboxypeptidase I (EC.3.4.15.1)
that activates angiotensin I through cleavage of the
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carboxyterminal dipeptide into the potent vasoconstrictor
angiotensin II (ang II), inactivating the vasodilator peptide
bradykinin. Recent evidence has indicated that activation of
the RAS pathway plays an important role in the develop-
ment and perpetuation of AF (15-17). ACE expression was
elevated in the atrial biopsies of patients with AF, and
angiotensin II concentrations were increased in a rapid
ventricular pacing-induced congestive heart failure model
of AF (2). Angiotensin II and bradykinin have also been
implicated in the modulation of cardiac growth (25).
Experimental studies have suggested that angiotensin II
might stimulate cardiac protein synthesis, whereas brady-
kinin may have anti-proliferative effects (26). In addition,
clinical evidence has suggested that inhibiting the activity of
RAS might suppress AF (18). ACE is a key enzyme in the
production of angiotensin II and in the degradation of
bradykinin (27). Our previous study, conducted in Chinese
EH patients, showed that the ACE 2350 G/A polymorphism
was associated with left ventricular hypertrophy but not EH
(23). These experimental and clinical data were suggestive
of a possible role for ACE in AF.
Over the past decade, much attention has been devoted to
assessing the role of the ACE gene I/D polymorphism in AF
after Rigat et al. (28) reported that more than half of the
plasma ACE levels among individuals were under the
influence of the I/D polymorphism. Yamashita et al. (29) first
investigated the ACE gene I/D polymorphism in 77 Japanese
lone AF patients and found that the distribution of ACE
genotypeswas not significantly different between the patients
and healthy controls. The subsequent studies, however,
yielded inconsistent and even contradictory results (2).
The ACE gene I/D polymorphic locus is located in a non-
coding region; therefore, it is more likely to be a genetic
marker in linkage disequilibrium with the genuine func-
tional variation locus (23). Zhu et al. (21) conducted a
linkage and association analysis of 13 polymorphic loci of
the ACE gene, demonstrating that the 2350 G/A poly-
morphic locus at exon 17 had the greatest effect on the
plasma ACE levels: approximately 19% of the variations in
the plasma ACE levels were associated with this poly-
morphism. The I/D polymorphism was no longer related to
the plasma ACE levels after adjustment for the effects of the
ACE 2350 G/A polymorphism. The results indicated that
the I/D polymorphism was in linkage disequilibrium with
2350 G/A and not the functional variation locus.
We did not test the linkage disequilibrium between the I/
D and 2350 G/A polymorphisms in the present study.
However, published studies, conducted in Emirati (30),
Punjab (31), and Indian (32) populations, have shown that
the ACE I/D and ACE 2350 G/A polymorphisms were in
strong linkage disequilibrium. The 2350 G/A polymorphic
locus, being located in an intron, is unlikely to influence the
Table 1 - Clinical characteristics of the AF and control subjects.
Characteristics AF (n= 75) Controls (n = 94) p-value
Age (years) 71.63¡8.62(63-82) 71.25¡8.17(60-85) 0.7708
Gender (% male) 62.67 64.89 0.7646
SBP (mm Hg) 145.33¡24.86 143.21¡23.75 0.5713
DBP (mm Hg) 81.76¡10.37 83.31¡11.44 0.3632
BMI (kg/m2) 23.54¡3.37 23.86¡3.78 0.5671
LVEF (%) 59.86¡6.21 61.27¡6.59 0.1536
Left atrial dimension (mm) 48.16¡7.13 37.42¡6.82 0.0000
TC (mmol/L) 4.86¡0.59 4.72¡0.51 0.1001
LDL-C (mmol/L) 2.50¡0.41 2.54¡0.46 0.5566
HDL-C (mmol/L) 1.41¡0.25 1.47¡0.29 0.1576
TG (mmol/L) 1.60¡0.52 1.53¡0.48 0.3654
Diabetes mellitus (%) 21.33 24.47 0.6308
Smoking (%) 17.33 11.70 0.2974
Diuretics (%) 38.67 28.72 0.1724
Calcium antagonist (%) 48.00 48.94 0.9037
b-blockers (%) 34.67 26.60 0.2561
ACE inhibitors (%) 50.67 54.26 0.6425
ARB (%) 29.33 32.98 0.6118
AF, atrial fibrillation; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; LVEF, left ventricular ejection fraction; TC, total
cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
Table 2 - ACE 2350G/A genotype and allele frequencies in AF and control subjects.
Genotype frequencies
(n,%) AF (n= 75) Controls (n = 94) Odds Ratio (95%CI) p-value Odds ratio* (95%CI) p-value
GG 14 (18.67) 38 (40.43) - - - -
GA 35 (46.67) 39 (41.49) 2.4359 (1.1346-5.2297) 0.0261 2.3368 (1.1000-4.9644) 0.0409
AA 26 (34.66) 17 (18.08) 4.1513 (1.7469-9.8650) 0.0016 3.1158 (1.3320-7.2885) 0.0117
Allele frequencies (n, %)
G 63 (42.00) 115 (61.17) - - - -
A 87 (58.00) 73 (38.83) 2.1755 (1.4050-3.3685) 0.0007 2.0486 (1.3274-3.1615) 0.0015
AF, atrial fibrillation; CI, confidence interval.
*Adjusted for gender, age, BMI, blood pressure, LVEF, plasma lipid parameters, smoking status, prevalence of diabetes, and left atrial dimensions.
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expression of ACE mRNA directly or to be a functional
variant. This fragment has been hypothesized to also be in
linkage disequilibrium with an unknown DNA fragment
that acts as a silencer. Therefore, the identification of these
putative gene loci, which would be in linkage disequili-
brium with the 2350 G/A polymorphism, requires further
investigation.
The correlation between the ACE 2350 G/A polymorph-
ism and AF has not yet been studied. In the present study,
there was a strong association between the ACE 2350 G/A
polymorphism and the risk of developing AF in EH
patients. Compared with the wild-type GG genotype, the
GA and AA genotypes showed 2.44-fold and 4.15-fold
increased risks of AF, respectively. In the AF group, AA
homozygotes also had greater left atrial dimensions than the
GG homozygotes and GA heterozygotes. These findings
suggest a strong association between the ACE 2350 G/A
polymorphism and the risk of developing AF in Han
Chinese patients with EH.
The ACE 2350 G/A polymorphism is a synonymous
mutation; this type of mutation has traditionally been
regarded as ‘‘silent’’. Recently, Duan et al. (33) reported a
synonymous mutation of the human dopamine receptor D2
(DRD2). In contrast to the previous idea that this type of
mutation was ‘‘silent’’, this synonymous mutation could
change mRNA folding, leading to a decrease in the stability
and transcription level of the mRNA and remarkably up-
regulating the DRD2 induced by dopamine. That study
indicated that some synonymous mutations might also
influence some functional effects. However, the ACE
2350G/A polymorphism might not be the actual functional
mutation in this context. It might be located near another
functional mutation, as yet undiscovered, in ACE or any
other gene in this region of chromosome 17 that could be in
LD. Thus, the mechanisms of the association of the ACE
2350G/A polymorphism with AF and the ACE concentra-
tions should be examined in future studies.
Previous case-control studies have shown that the
frequency of the A allele in Chinese healthy controls is
0.417-0.451 (19,23,24). The A allele frequency in Chinese
subjects was significantly greater (p,0.05) than those in a
Pakistani population (0.298) (34) and a Malaysian cohort
(0.207) (35) but lower (p,0.05) than those in a European
sample (0.513–0.542) (36) and an Iranian sample (0.591) (37).
These data indicate that different ethnic groups might have
different ACE gene distributions (38) and that ethnic
variation could play a major role in the genetic regulation
of serum ACE activity (24).
This study has several potential limitations. First, we
could not exclude the presence of previous asymptomatic
AF in the control group because these conclusions were
based solely on the medical histories obtained from inter-
views with the participants. Second, the absence of the
assessment of serum ACE levels concordant with the ACE
2350G/A polymorphism might have limited the outcomes.
Finally, although all the study subjects were from the Han
Chinese population and the possibility of ethnicity as a
confounding factor could thus be excluded, the association
of the ACE 2350G/A polymorphism and AF in other
populations remains unknown and requires further study.
In conclusion, our data indicate that the ACE 2350G/A
polymorphism is associated with AF and that the A allele
shows an increased risk for AF in Han Chinese patients with
EH. The ACE 2350 G/A polymorphism should be evaluated
in EH patients to quantify the risk of AF and, consequently,
to improve efforts for preventing or delaying the myocardial
remodeling associated with EH. Given the inherent limita-
tions of case-control studies and the complex nature of
genetic susceptibility for chronic degenerative diseases,
prospective and interventional clinical studies with larger
sample sizes will still need to be conducted in individual
ethnic groups to verify our observations.
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